×
About 3,661 results

ALLMedicine™ Peritoneal Cancer Center

Research & Reviews  1,705 results

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patien...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813404
BMJ Open; Mansouri A, McGregor N et. al.

Jan 16th, 2021 - Patients relapsing within 12 months of platinum-based chemotherapy usually have a poorer response to subsequent treatments. To date, extensive research into the mechanism of resistance to platinum agents in the treatment of ovarian cancer has not ...

High grade, advanced, serous ovarian cancer with low serum CA125 levels.
https://doi.org/10.1080/01443615.2020.1835844
Journal of Obstetrics and Gynaecology : the Journal of Th... Asali A, Haj-Yehia N et. al.

Jan 11th, 2021 - This study compares characteristics of advanced stage, high grade serous ovarian cancer, presenting with high or low serum CA125 level. This was a retrospective cohort of 118 patients with high grade serous ovarian, fallopian tube or primary perit...

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798203
Journal of Ovarian Research; Yuan Z, Zhang Y et. al.

Jan 11th, 2021 - To evaluate the efficacy and safety of PLD in treating of in patients who experience epithelial ovarian, fallopian tubal, and peritoneal cancer progression within 12 months after the first-line platinum-based therapy. This was an open-label, singl...

A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination wit...
https://doi.org/10.1016/j.ygyno.2020.12.025
Gynecologic Oncology; Duska LR, Krasner CN et. al.

Jan 4th, 2021 - EP0057 (formerly CRLX101) is an investigational nanoparticle-drug conjugate (NDC) of a cyclodextrin-based polymer backbone plus camptothecin, a topoisomerase-1 inhibitor. Prior studies showed efficacy in recurrent or persistent, epithelial ovarian...

see more →

Guidelines  19 results

FDA approves niraparib for first-line maintenance of advanced ovarian cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA

Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response ...

FDA approves niraparib for HRD-positive advanced ovarian cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer

Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer...

BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing
https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing1

Aug 20th, 2019 - The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations...

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer - US Preventive Services Task Force Recommendation Statement
https://jamanetwork.com/journals/jama/fullarticle/2748515

Aug 19th, 2019 - Importance Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is t...

Cancer incidence in the Agricultural Health Study after 20 years of follow-up
https://link.springer.com/article/10.1007%2Fs10552-019-01140-y
Cancer Causes & Control; Lerro,C.,et al

Feb 24th, 2019 - To evaluate cancer incidence in the Agricultural Health Study (AHS), a cohort of private pesticide applicators, their spouses, and commercial applicators, based on 12,420 cancers, adding 5,989 cancers, and 9 years of follow-up since last evaluatio...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  1,839 results

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patien...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813404
BMJ Open; Mansouri A, McGregor N et. al.

Jan 16th, 2021 - Patients relapsing within 12 months of platinum-based chemotherapy usually have a poorer response to subsequent treatments. To date, extensive research into the mechanism of resistance to platinum agents in the treatment of ovarian cancer has not ...

NICE Approves 'Game-changing' Ovarian Cancer Drug
https://www.medscape.com/viewarticle/944178

Jan 14th, 2021 - Niraparib (Zejula, GlaxoSmithKline) has been approved by the National Institute for Health and Care Excellence (NICE) for England's Cancer Drugs Fund (CDF) for some women with advanced ovarian cancer. The decision means the drug should also be ava...

High grade, advanced, serous ovarian cancer with low serum CA125 levels.
https://doi.org/10.1080/01443615.2020.1835844
Journal of Obstetrics and Gynaecology : the Journal of Th... Asali A, Haj-Yehia N et. al.

Jan 11th, 2021 - This study compares characteristics of advanced stage, high grade serous ovarian cancer, presenting with high or low serum CA125 level. This was a retrospective cohort of 118 patients with high grade serous ovarian, fallopian tube or primary perit...

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798203
Journal of Ovarian Research; Yuan Z, Zhang Y et. al.

Jan 11th, 2021 - To evaluate the efficacy and safety of PLD in treating of in patients who experience epithelial ovarian, fallopian tubal, and peritoneal cancer progression within 12 months after the first-line platinum-based therapy. This was an open-label, singl...

see more →

News  89 results

NICE Approves 'Game-changing' Ovarian Cancer Drug
https://www.medscape.com/viewarticle/944178

Jan 14th, 2021 - Niraparib (Zejula, GlaxoSmithKline) has been approved by the National Institute for Health and Care Excellence (NICE) for England's Cancer Drugs Fund (CDF) for some women with advanced ovarian cancer. The decision means the drug should also be ava...

ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer
https://www.medscape.com/viewarticle/939945

Oct 27th, 2020 - New guidelines recommend against retreatment with poly (ADP-ribose) polymerase (PARP) inhibitors in women with epithelial ovarian, tubal, or primary peritoneal cancer (EOC). However, trials investigating retreatment are underway, so this recommend...

FDA approves niraparib for first-line maintenance of advanced ovarian cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA

Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response ...

Is it time to expand the use of PARP inhibitors?
https://www.mdedge.com/hematology-oncology/article/210908/genitourinary-cancer/it-time-expand-use-parp-inhibitors/page/0/1?channel=61051

Oct 25th, 2019 - Advanced ovarian cancer The randomized, double-blind, placebo-controlled, phase 3 PAOLA-1/ENGOT-ov25 trial studied patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer who had surgery, platinum-taxane chemotherapy, and.

see more →